Related references
Note: Only part of the references are listed.Predictive and sensitive biomarkers for thyroid dysfunctions during treatment with immune-checkpoint inhibitors
Chiaki Kurimoto et al.
CANCER SCIENCE (2020)
Immune checkpoint inhibitor-associated pituitary adverse events: an observational, retrospective, disproportionality study
X. Bai et al.
JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION (2020)
Immune Checkpoint Inhibitor-Associated Primary Adrenal Insufficiency: WHO VigiBase Report Analysis
Virginie Grouthier et al.
ONCOLOGIST (2020)
Correlation between immune-related adverse events and prognosis in patients with various cancers treated with anti PD-1 antibody
Hiroshi Matsuoka et al.
BMC CANCER (2020)
ICPis-Induced Autoimmune Polyendocrine Syndrome Type 2: A Review of the Literature and a Protocol for Optimal Management
Yun Shi et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2020)
Endocrine Toxicity of Cancer Immunotherapy Targeting Immune Checkpoints
Lee-Shing Chang et al.
ENDOCRINE REVIEWS (2019)
French Endocrine Society Guidance on endocrine side effects of immunotherapy
F. Castinetti et al.
ENDOCRINE-RELATED CANCER (2019)
Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors
Satya Das et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
Anti-PD-L1 Treatment Induced Central Diabetes Insipidus
Chen Zhao et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2018)
Characterization and implications of thyroid dysfunction induced by immune checkpoint inhibitors in real-life clinical practice: a long-term prospective study from a referral institution
F. Guaraldi et al.
JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION (2018)
On type 1 diabetes mellitus pathogenesis
Stavroula A. Paschou et al.
ENDOCRINE CONNECTIONS (2018)
Testosterone Therapy in Men With Hypogonadism: An Endocrine Society* Clinical Practice Guideline
Shalender Bhasin et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2018)
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
Julie R. Brahmer et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Acute management of the endocrine complications of checkpoint inhibitor therapy
C. E. Higham et al.
ENDOCRINE CONNECTIONS (2018)
Incidence of Endocrine Dysfunction Following the Use of Different Immune Checkpoint Inhibitor Regimens A Systematic Review and Meta-analysis
Romualdo Barroso-Sousa et al.
JAMA ONCOLOGY (2018)
Aggravation of diabetes, and incompletely deficient insulin secretion in a case with type 1 diabetes-resistant human leukocyte antigen DRB1*15:02 treated with nivolumab
Kimio Matsumura et al.
JOURNAL OF DIABETES INVESTIGATION (2018)
Antibody-mediated thyroid dysfunction during T-cell checkpoint blockade in patients with non-small-cell lung cancer
J. C. Osorio et al.
ANNALS OF ONCOLOGY (2017)
A case of pembrolizumab-induced type-1 diabetes mellitus and discussion of immune checkpoint inhibitor-induced type 1 diabetes
Young Kwang Chae et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2017)
Fulminant type I diabetes mellitus associated with nivolumab in a patient with relapsed classical Hodgkin lymphoma
Wataru Munakata et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2017)
Case report: pembrolizumab-induced Type 1 diabetes in a patient with metastatic cholangiocarcinoma
Matthew A. Smith-Cohn et al.
IMMUNOTHERAPY (2017)
Pembrolizumab-Induced Thyroiditis: Comprehensive Clinical Review and Insights Into Underlying Involved Mechanisms
Danae A. Delivanis et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2017)
Characterization of Thyroid Disorders in Patients Receiving Immune Checkpoint Inhibition Therapy
Hyunju Lee et al.
CANCER IMMUNOLOGY RESEARCH (2017)
Nivolumab induced myxedema crisis
Uqba Khan et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2017)
Tremelimumab-Induced Graves Hyperthyroidism
Earn H. Gan et al.
EUROPEAN THYROID JOURNAL (2017)
Polyendocrinopathy Resulting From Pembrolizumab in a Patient With a Malignant Melanoma
Anne-Cecile Paepegaey et al.
JOURNAL OF THE ENDOCRINE SOCIETY (2017)
RAPID EVOLUTION OF THYROID DYSFUNCTION IN PATIENTS TREATED WITH NIVOLUMAB
Grenye O'Malley et al.
ENDOCRINE PRACTICE (2017)
Acute-onset type 1 diabetes mellitus caused by nivolumab in a patient with advanced pulmonary adenocarcinoma
Ryo Kumagai et al.
JOURNAL OF DIABETES INVESTIGATION (2017)
Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
J. B. A. G. Haanen et al.
ANNALS OF ONCOLOGY (2017)
A case of fulminant type 1 diabetes mellitus, with a precipitous decrease in pancreatic volume, induced by nivolumab for malignant melanoma: analysis of HLA and CTLA-4 polymorphisms
Kazushi Ishikawa et al.
EUROPEAN JOURNAL OF DERMATOLOGY (2017)
Thyroid abnormalities following the use of cytotoxic T-lymphocyte antigen-4 and programmed death receptor protein-1 inhibitors in the treatment of melanoma
D. L. Morganstein et al.
CLINICAL ENDOCRINOLOGY (2017)
Autoimmune Diabetes and Thyroiditis Complicating Treatment with Nivolumab
Li Li et al.
CASE REPORTS IN ONCOLOGY (2017)
Hypophysitis Secondary to Cytotoxic T-Lymphocyte-Associated Protein 4 Blockade Insights into Pathogenesis from an Autopsy Series
Patrizio Caturegli et al.
AMERICAN JOURNAL OF PATHOLOGY (2016)
Incidence of Thyroid-Related Adverse Events in Melanoma Patients Treated With Pembrolizumab
Jeroen de Filette et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2016)
Hormonal Replacement in Hypopituitarism in Adults: An Endocrine Society Clinical Practice Guideline
Maria Fleseriu et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2016)
Diagnosis and Treatment of Primary Adrenal Insufficiency: An Endocrine Society Clinical Practice Guideline
Stefan R. Bornstein et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2016)
Fulminant type1 diabetes mellitus with anti-programmed cell death-1 therapy
Masahide Okamoto et al.
JOURNAL OF DIABETES INVESTIGATION (2016)
Association of Serum Anti-GAD Antibody and HLA Haplotypes with Type 1 Diabetes Mellitus Triggered by Nivolumab in Patients with Non–Small Cell Lung Cancer
Yuko Usui et al.
Journal of Thoracic Oncology (2016)
Ipilimumab-Induced Adrenalitis A Possible Pitfall in 18F-FDG-PET/CT
Sara Bacanovic et al.
CLINICAL NUCLEAR MEDICINE (2015)
Anti-PD1 Pembrolizumab Can Induce Exceptional Fulminant Type 1 Diabetes
Caroline Gaudy et al.
DIABETES CARE (2015)
Induction of Painless Thyroiditis in Patients Receiving Programmed Death 1 Receptor Immunotherapy for Metastatic Malignancies
Steven Orlov et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2015)
Diagnosis and management of adrenal insufficiency
Irina Bancos et al.
LANCET DIABETES & ENDOCRINOLOGY (2015)
Systemic High-Dose Corticosteroid Treatment Does Not Improve the Outcome of Ipilimumab-Related Hypophysitis: A Retrospective Cohort Study
Le Min et al.
CLINICAL CANCER RESEARCH (2015)
Precipitation of Autoimmune Diabetes With Anti-PD-1 Immunotherapy
Jing Hughes et al.
DIABETES CARE (2015)
Long-term follow-up of ipilimumab-induced hypophysitis, a common adverse event of the anti-CTLA-4 antibody in melanoma
Frederique Albarel et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2015)
Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institution
Mabel Ryder et al.
ENDOCRINE-RELATED CANCER (2014)
Ipilimumab-Induced Hypophysitis: A Detailed Longitudinal Analysis in a Large Cohort of Patients With Metastatic Melanoma
Alexander T. Faje et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2014)
Ipilimumab-Induced Hypophysitis and Uveitis in a Patient With Metastatic Melanoma and a History of Ipilimumab-Induced Skin Rash
Neelima N. Nallapaneni et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2014)
Ipilimumab-induced autoimmune adrenalitis
Le Min et al.
LANCET DIABETES & ENDOCRINOLOGY (2013)
Hypophysitis Induced by Monoclonal Antibodies to Cytotoxic T Lymphocyte Antigen 4: Challenges from a New Cause of a Rare Disease
Francesco Torino et al.
ONCOLOGIST (2012)
The blockade of immune checkpoints in cancer immunotherapy
Drew M. Pardoll
NATURE REVIEWS CANCER (2012)
Evaluation and Treatment of Adult Growth Hormone Deficiency: An Endocrine Society Clinical Practice Guideline
Mark E. Molitch et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2011)
The emerging role of CTLA4 as a cell-extrinsic regulator of T cell responses
Lucy S. K. Walker et al.
NATURE REVIEWS IMMUNOLOGY (2011)
The PD-1 pathway in tolerance and autoimmunity
Loise M. Francisco et al.
IMMUNOLOGICAL REVIEWS (2010)
Anti-CTLA-4 antibody therapy associated autoimmune hypophysitis: serious immune related adverse events across a spectrum of cancer subtypes
Troy Dillard et al.
PITUITARY (2010)
CD4+ regulatory T cells require CTLA-4 for the maintenance of systemic tolerance
Randall H. Friedline et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2009)
Tissue expression of PD-L1 mediates peripheral T cell tolerance
ME Keir et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2006)
CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms
RV Parry et al.
MOLECULAR AND CELLULAR BIOLOGY (2005)
Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade
Y Iwai et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2002)
Share Paper
